Analysis conducted by the FDA (Food and Drug Administration) show that Americans ARB class of antihypertensive drugs (Angiotensin Receptor Blockers) does not cause the incidence of new cancers in patients. This statement was delivered by the U.S. FDA in connection with the results of controversial meta-analysis conducted by dr. Ilke Sipahi and colleagues from University Hospitals Case Medical Center, Cleveland, Ohio, United States, which showed that therapy with an ARB can lead to new cancer. The announcement from the FDA regarding the lack of association between cancer therapy with the ARB must clarify this controversial news.
Experimental studies show that the renin angiotensin system, particularly angiotensin receptor type 1 and type 2, associated with cell proliferation, angiogenesis and tumor progression. The results of experimental studies
are encouraging dr. Ilke Sipahi and colleagues to conduct a meta-analysis of whether there is an increased risk of cancer with ARB therapy, by collecting the results of studies with designs that use random terontrol ARB.
Based on the results of this meta-analysis, dr. Ilke Sipahi said that the use of ARB therapy associated with the incidence of new cancers. Yet experts in the study also said that the data are limited and do not allow to establish a definite cancer risk in relation to each of the ARB class of drugs. Dr. Ilke Sipahi also recommends further research on this subject.
News of the possible risk of cancer research dr. Ilke Sipahi and colleagues have become hot news that has been widely criticized by many specialists hypertension, considering that many patients treated with ARB medications, and with this news patients may stop taking the drug. In addition to the FDA, EMA (European Medicines Agency) The very first response to the results of research conducted by dr. Ilke Sipahi, still doing his review in connection with this news.
Analysis conducted by the FDA, showed that the incidence of cancer in group therapy using ARBs was 1.82% per 100 patients per year, dibandinkan with non-ARB group of 1.84 per 100 patient-years. Comparisons between groups was not found significantly different, after analysis using any statistical, or a comparison group taking placebo or other non-ARB drugs, and did not appear increased risk of cancer in patients treated with ARB.
After doing analisia, responding to research results dr. Ilke Sipahi and colleagues, Dr. Mary Ross Southworth, the deputy director for safety in the Division of Cardiovascular and Renal Drugs in the FDA's Center for Drug Evaluation and Research, representing the FDA said that the meta-analysis carried out still has some drawbacks, including the amount of research limited, the ARB telmisartan is the most widely used, and the research conducted was not designed to put the cancer as an endpoint. Therefore needs to be done is a meta-analysis of controlled studies are larger, with a duration of at least 1 year and the use of standard-dose ARB.
No comments:
Post a Comment